Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11038805 | 1.00 | MAPT (0.35) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL11172061 | 1.00 | MAPT (0.35) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL11172066 | 1.00 | MAPT (0.35) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL11038803 | 1.00 | MAPT (0.35) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL1230297 | 1.00 | MAPT (0.35) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL1230296 | 1.00 | MAPT (0.35) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL11038808 | 1.00 | MAPT (0.35) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL14434930 | 0.98 | MAPT (0.36) | MAPTRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL1785347 | 0.91 | — | — | |
| SCHEMBL27626844 | 0.83 | RAB9A (0.33) | MAPTRAB9ANPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | MAPT 2466/4885RAB9A 1583/4885NPC1 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.